Stockreport

Compass Therapeutics Provides Corporate Update

Compass Therapeutics, Inc.  (CMPX) 
PDF The analyses of progression-free survival (PFS) and overall survival (OS) remain on track for late Q1 2026 in the ongoing Phase 2/3 COMPANION-002 study of tovecimig (DLL [Read more]